Dr. Reddy’s Laboratories has filed a patent for pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof. The patent claims a method for treating cancer by administering the compound to a subject in need. GlobalData’s report on Dr. Reddy’s Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dr. Reddy's Laboratories, cancer treatment biomarkers was a key innovation area identified from patents. Dr. Reddy's Laboratories's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating cancer
A recently filed patent (Publication Number: US20230167076A1) describes a method for treating cancer in a subject. The method involves administering a compound to the subject, with the specific compound being selected from a list of options. The patent claims cover various types of cancer, including non-Hodgkin's lymphoma, leukemia, and lymphoma.
The first claim of the patent outlines the general method for treating cancer in a subject by administering a compound. The subsequent claims provide specific details about the types of cancer that can be treated using this method. Claims 2, 6, and 10 specify non-Hodgkin's lymphoma as the targeted cancer, while claims 3, 7, and 11 focus on leukemia. Claims 4, 8, and 12 mention lymphoma as the cancer type.
The patent also includes claims related to the specific compound used in the treatment. Claim 5 introduces the compound, and subsequent claims (13 and 17) further specify that the compound is a pharmaceutically acceptable salt. Claims 9 and 18 state that the compound can be a pharmaceutically acceptable salt of a certain substance.
Overall, this patent describes a method for treating cancer by administering a compound to a subject. The method can be applied to various types of cancer, including non-Hodgkin's lymphoma, leukemia, and lymphoma. The specific compound used in the treatment can be a pharmaceutically acceptable salt of a certain substance. This patent filing provides valuable information for researchers and pharmaceutical companies working on cancer treatments, potentially leading to the development of new therapies for these types of cancer.
To know more about GlobalData’s detailed insights on Dr. Reddy's Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
